VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Terme, Magali ^a   Tartour, Eric ^a,b   Taieb, Julien ^a,b  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Colorectal cancer; Immunosuppression; Proliferation; Regulatory t cells; Tumor; Vegf a

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL MATURATION; COLORECTAL CANCER; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; KIDNEY METASTASIS; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T CELL DEPLETION; TUMOR MICROENVIRONMENT;

EID: 84885751156     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25156     Document Type: Article

References (10)

1. Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114:379-88; PMID:15286804
2. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immunebased cancer therapies. Cancer Res 2009; 69:2514-22; PMID:19276342; http://dx.doi.org/10.1158/0008- 5472.CAN-08-4709
3. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078- 0432.CCR-08-1332
4. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14:6674-82; PMID:18927310; http://dx.doi. org/10.1158/1078-0432.CCR-07-5212
5. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33:991-8; PMID:20948437; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208
6. Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, et al. Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance. Cancer Microenviron 2012; PMID:23104434; http://dx.doi.org/10.1007/ s12307-012-0122-y
7. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73:539-49; PMID:23108136; http://dx.doi. org/10.1158/0008-5472.CAN-12-2325
8. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010; 70:9599-610; PMID:21118964; http://dx.doi.org/10.1158/0008- 5472.CAN-10-1293
9. Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012; 2012:492920; PMID:23320019; http://dx.doi. org/10.1155/2012/492920
10. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-66; PMID:9834220